Genetic variants in theTEP1gene are associated with prostate cancer risk and recurrence

    loading  Checking for direct PDF access through Ovid

Abstract

BACKGROUND:

Telomere-related genes play an important role in carcinogenesis and progression of prostate cancer (PCa). It is not fully understood whether genetic variations in telomere-related genes are associated with development and progression in PCa patients.

METHODS:

Six potentially functional single-nucleotide polymorphisms (SNPs) of three key telomere-related genes were evaluated in 1015 PCa cases and 1052 cancer-free controls, to test their associations with risk of PCa. Among 426 PCa patients who underwent radical prostatectomy (RP), the prognostic significance of the studied SNPs on biochemical recurrence (BCR) was also assessed using the Kaplan-Meier analysis and Cox proportional hazards regression model. The relative telomere lengths (RTLs) were measured in peripheral blood leukocytes using real-time PCR in the RP patients.

RESULTS:

TEP1 rs1760904 AG/AA genotypes were significantly associated with a decreased risk of PCa (odds ratio (OR): 0.77, 95% confidence interval (CI): 0.64–0.93, P = 0.005) compared with the GG genotype. By using median RTL as a cutoff level, RP patients with TEP1 rs1760904 AG/AA genotypes tended to have a longer RTL than those with the GG genotype (OR: 1.55, 95% CI: 1.04–2.30, P = 0.031). A significant interaction between TEP1 rs1713418 and age in modifying PCa risk was observed (P = 0.005). After adjustment for clinicopathologic risk factors, the presence of heterozygotes or rare homozygotes of TEP1 rs1760904 and TNKS2 rs1539042 were associated with BCR in the RP cohorts (hazard ratio: 0.53, 95% CI: 0.36–0.79, P = 0.002 and hazard ratio: 1.67, 95% CI: 1.07–2.48, P = 0.017, respectively).

CONCLUSIONS:

These data suggest that genetic variations in the TEP1 gene may be biomarkers for risk of PCa and BCR after RP.

Related Topics

    loading  Loading Related Articles